ABIVAX Société Anonyme (NASDAQ:ABVX) Shareholder/Analyst Call October 6, 2025 9:00 AM EDT
Company Participants
Patrick Malloy – Senior Vice President of Investor Relations
Marc M. de Garidel – CEO & Director
Chris Rabbat – VP & Global Head of Medical Affairs
Fabio Cataldi – Chief Medical Officer
Conference Call Participants
Marla C. Dubinsky, MD
Yatin Suneja – Guggenheim Securities, LLC, Research Division
Julian Harrison – BTIG, LLC, Research Division
Samuel Slutsky – LifeSci Capital, LLC, Research Division
Jason Butler – Citizens JMP Securities, LLC, Research Division
Thomas Smith – Leerink Partners LLC, Research Division
Judah Frommer – Morgan Stanley, Research Division
Sebastiaan van der Schoot
Yale Jen – Laidlaw & Company (UK) Ltd., Research Division
Presentation
Operator
Good day, and thank you for standing by. Welcome to the ABIVAX management call to discuss late-breaking ABTECT at UEG Conference. [Operator Instructions] Please be advised that today’s conference is being recorded.
I would now like to hand the conference over to your speaker today, Pat Malloy. Please go ahead.
Patrick Malloy
Senior Vice President of Investor Relations
Great. Thank you, Sandra, and good morning and good afternoon to everybody, and thank you for joining today’s call to discuss the results of the late-breaking ABTECT presented at this week’s UEG meeting in Berlin. Joining me on today’s call are our Chief Executive Officer, Marc de Garidel; Chief Medical Officer, Fabio Cataldi; Chief Financial Officer, Didier Blondel; and Head of Medical Affairs, Chris Rabbat.
We are also fortunate to have Dr. Marla Dubinsky joining us today to provide an overview of the data presented at [ UEGW ]. Dr. Dubinsky is a Professor of Pediatrics and Medicine and Co-Director of the Susan and Leonard Feinstein IBD Clinical Center at Mount Sinai Hospital. Following Dr. Dubinsky’s presentation, we’ll move to a Q&A session.
Before I hand the call over to Marc to make some
Credit: Source link
